PathAI
Founded Year
2016Stage
Series C | AliveTotal Raised
$255MLast Raised
$165M | 1 yr agoAbout PathAI
PathAI provides AI-powered research tools and services for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
PathAI Headquarter Location
1325 Boylston St. Suite 10000
Boston, Massachusetts, 02215,
United States
ESPs containing PathAI
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Computer-aided diagnostic imaging utilizes algorithms to detect, extract, and communicate data from medical images more efficiently and accurately than the human eye. The technology is being deployed across several imaging modalities to improve the detection, diagnosis, triaging, and, ultimately, the prognosis of various medical conditions.
PathAI named as Leader among 15 other companies, including Ibex Medical Analytics, Lunit, and Aidoc Medical.
Research containing PathAI
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned PathAI in 11 CB Insights research briefs, most recently on Feb 16, 2022.
Feb 16, 2022
The 130+ AI startups reinventing healthcare
Expert Collections containing PathAI
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PathAI is included in 9 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
8,717 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Digital Health 150
450 items
2019's cohort of the most promising digital health startups transforming the healthcare industry
Medical Devices
8,324 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Health Monitoring & Diagnostics
2,707 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
PathAI Patents
PathAI has filed 5 patents.
The 3 most popular patent topics include:
- Artificial neural networks
- Classification algorithms
- Clusters of differentiation
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/7/2020 | 12/7/2021 | Machine learning, Classification algorithms, Artificial neural networks, Transcription factors, Clusters of differentiation | Grant |
Application Date | 4/7/2020 |
|---|---|
Grant Date | 12/7/2021 |
Title | |
Related Topics | Machine learning, Classification algorithms, Artificial neural networks, Transcription factors, Clusters of differentiation |
Status | Grant |
Latest PathAI News
May 2, 2022
PathAI and Cleveland Clinic aim to change that have embarked on a five-year research collaboration. This partnership will involve digitizing pathology specimens and linking clinical data with digitized pathology data.
PathAI Web Traffic
PathAI Rank
When was PathAI founded?
PathAI was founded in 2016.
Where is PathAI's headquarters?
PathAI's headquarters is located at 1325 Boylston St., Boston.
What is PathAI's latest funding round?
PathAI's latest funding round is Series C.
How much did PathAI raise?
PathAI raised a total of $255M.
Who are PathAI's competitors?
Competitors of PathAI include Deciphex, Nucleai, Lunit, Ibex Medical Analytics, Diagu and 10 more.
You May Also Like
Paige delivers AI-powered digital diagnostics and biomarkers for pathologists, oncologists, and the R&D community worldwide, while also working closely with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads/chairs as well as life sciences research and translational teams.
Proscia is a software company focused on transforming cancer research and diagnosis. With the company's Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries.
Ibex Medical Analytics develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. Ibex develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. The company was founded in 2016 and is based in Israel.
Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.
DeepBio is a developer of prostate cancer diagnosis software. The company's product features a convolutional neural network that detects and grades prostate cancer from needle biopsy images.
Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.